approxim
million
new
case
occur
worldwid
annual
geneva
human
trichomoniasi
far
preval
sexual
transmit
diseas
std
either
chlamydia
caus
chlamydia
trachomati
gonorrhoea
caus
neisseria
gonorrhoea
soper
caus
organ
diseas
human
trichomona
vaginali
primarili
acquir
transmiss
trophozoit
direct
sexual
contact
although
neonat
infect
also
report
mclaren
et
al
metronidazol
mtz
current
fdaapprov
treatment
diseas
use
year
howev
ampl
report
develop
resist
isol
mtz
certain
case
shown
tackl
prolong
therapi
higher
dosag
wright
et
al
upcroft
et
al
entrench
trichomoniasisinfect
patient
suscept
toward
human
immunodefici
viru
hiv
appear
cofactor
hiv
transmiss
acquisit
sorvillo
et
al
van
der
pol
et
al
signific
increas
vulner
hiv
trichomoniasi
mcclelland
et
al
guenthner
et
al
increas
import
diseas
dramat
evid
identif
develop
novel
scaffold
toxic
vaginali
minim
cytotox
human
cell
challeng
task
provid
strong
impetu
reengin
reposit
previous
character
drug
famili
upcroft
et
al
isatin
privileg
scaffold
well
toler
human
analogu
demonstr
divers
rang
biolog
pharmacolog
properti
antihiv
bal
et
al
antivir
quenel
et
al
anticanc
vine
lock
kopka
et
al
antifung
raj
et
al
anticonvuls
verma
et
al
antiparkinson
diseas
therapeut
igosheva
et
al
inhibitor
casey
et
al
hadfield
et
al
effect
sar
coronaviru
proteas
inhibitor
chen
et
al
enthral
applic
isatin
organ
synthesi
biolog
properti
well
occurr
natur
product
spirotryprostatin
horsfilin
gelsemin
gelseverin
rhynchophyllin
elacomin
etc
gener
tremend
interest
among
synthet
organ
medicin
chemist
fensom
et
al
kumari
et
al
ding
et
al
vintonyak
et
al
rottmann
et
al
particular
exampl
deriv
semaxanib
sunitinib
report
tyrosin
kinas
inhibitori
antiangiogen
properti
et
al
prenen
et
al
crucial
structur
unit
present
wide
class
antibiot
palomo
et
al
palomo
et
al
follow
discoveri
penicillin
array
natur
occur
antibiot
introduc
chemotherapeut
incompar
effect
treatment
bacteri
infect
current
interest
famili
focus
synthesi
modif
ring
obtain
compound
divers
pharmacolog
potenti
tumour
necrosi
factoralpha
tnfalpha
convert
enzym
tace
inhibitor
rao
et
al
anticanc
boyl
et
al
singh
et
al
anticoccidi
liang
et
al
cardiovascular
takai
et
al
antivir
hoogh
et
al
mutagen
gutierrez
et
al
antifung
driscol
et
al
antimalari
activ
jarrahpour
et
al
besid
emin
heterocycl
system
numer
biolog
potenti
also
employ
synthet
precursor
synthesi
wide
varieti
heterocycl
scaffold
singh
alcaid
et
al
hoogh
et
al
singh
et
al
recent
pharmacophor
hybrid
appear
attract
paradigm
medicin
chemist
main
incent
use
strategi
relat
mark
improv
therapeut
potenti
potenc
mode
action
pharmacokinet
meunier
muregi
ishih
morphi
rankov
continu
effort
synthesi
novel
molecular
conjug
biolog
potenti
raj
et
al
raj
et
al
nisha
et
al
kumar
et
al
kumar
et
al
recent
discuss
synthesi
conjug
vitro
evalu
vaginali
raj
et
al
synthes
compound
exhibit
growth
inhibit
potent
noncytotox
compound
fig
display
valu
present
commun
extens
approach
compris
synthesi
mono
bifunct
hybrid
isatin
substitut
fig
preliminari
vitro
evalu
studi
vaginali
rational
behind
use
linker
activ
particip
hydrogen
bond
interact
stabil
hydrolysi
oxidativereduct
condit
kolb
et
al
kolb
sharpless
wang
et
al
bock
et
al
brick
red
colour
yield
ir
kbr
mp
nmr
mhz
j
hz
dd
j
hz
dd
j
hz
j
hz
arh
j
hz
arh
triazoleh
nmr
mhz
ppm
hrm
calcul
found
anal
calcd
c
h
n
found
c
h
n
brick
red
colour
yield
ir
kbr
mp
nmr
mhz
cyclohexyl
cyclohexyl
j
hz
dd
j
hz
dd
j
hz
dd
j
hz
j
hz
arh
triazoleh
nmr
mhz
ppm
hrm
calcul
found
anal
calcd
c
h
n
found
c
h
n
brick
red
colour
yield
ir
kbr
mp
nmr
mhz
j
hz
dd
j
hz
dd
j
hz
j
hz
arh
j
hz
arh
triazoleh
nmr
mhz
ppm
hrm
calcul
found
anal
calcd
c
h
n
found
c
h
n
brick
red
colour
yield
ir
kbr
mp
nmr
mhz
dd
j
hz
pair
doublet
j
hz
dd
j
hz
j
hz
dd
j
hz
dd
j
hz
j
hz
arh
j
hz
j
hz
arh
arh
triazoleh
nmr
mhz
ppm
hrm
calcul
found
anal
calcd
c
h
n
found
c
h
n
brick
red
colour
yield
ir
kbr
mp
nmr
mhz
cyclohexyl
dd
j
hz
cyclohexyl
j
hz
dd
j
hz
dd
j
hz
j
hz
arh
triazoleh
nmr
mhz
ppm
hrm
calcul
found
anal
calcd
c
h
n
found
c
h
n
brick
red
colour
yield
ir
kbr
mp
nmr
mhz
dd
j
hz
j
hz
dd
j
hz
dd
j
hz
j
hz
arh
j
hz
arh
triazoleh
nmr
mhz
ppm
hrm
calcul
found
anal
calcd
c
h
n
found
c
h
n
brick
red
colour
yield
ir
kbr
mp
nmr
mhz
pair
doublet
j
hz
dd
j
hz
dd
j
hz
dd
j
hz
j
hz
arh
j
hz
j
hz
arh
j
hz
arh
arh
triazoleh
nmr
mhz
ppm
hrm
calcul
found
anal
calcd
c
h
n
found
c
h
n
brick
red
colour
yield
ir
kbr
mp
nmr
mhz
cyclohexyl
cyclohexyl
pair
doublet
j
hz
j
hz
dd
j
hz
dd
j
hz
dd
j
hz
j
hz
arh
triazoleh
nmr
mhz
ppm
hrm
calcul
found
anal
calcd
c
h
n
found
c
h
n
brick
red
colour
yield
ir
kbr
mp
nmr
mhz
j
hz
dd
j
hz
dd
j
hz
dd
j
hz
j
hz
arh
j
hz
arh
triazoleh
nmr
mhz
ppm
hrm
calcul
found
anal
calcd
c
h
n
found
c
h
n
brick
red
colour
yield
ir
kbr
mp
nmr
mhz
dd
j
hz
j
hz
j
hz
dd
j
hz
dd
j
hz
j
hz
j
hz
arh
arh
triazoleh
nmr
mhz
ppm
hrm
calcul
found
anal
calcd
c
h
n
found
c
h
n
brick
red
colour
yield
ir
kbr
mp
nmr
mhz
cyclohexyl
dd
j
hz
cyclohexyl
j
hz
dd
j
hz
dd
j
hz
j
hz
arh
triazoleh
nmr
mhz
ppm
hrm
calcul
found
anal
calcd
c
h
n
found
c
h
n
brick
red
colour
yield
ir
kbr
mp
nmr
mhz
dd
j
hz
j
hz
dd
j
hz
dd
j
hz
j
hz
arh
j
hz
arh
triazoleh
nmr
mhz
ppm
hrm
calcul
found
anal
calcd
c
h
n
found
c
h
n
protozo
parasit
cultur
h
perform
initi
suscept
screen
vaginali
compound
suspend
dmso
obtain
concentr
aliquot
suspens
dilut
ml
tym
diamond
media
obtain
final
concentr
h
cell
count
use
hemacytomet
cell
count
normal
dmso
control
order
allow
direct
comparison
averag
variou
trial
data
set
transform
use
prism
softwar
graphpad
take
log
drug
concentr
trial
input
transform
log
inhibitor
versu
slope
regress
option
within
nonlinear
regress
constraint
set
forc
maximum
valu
top
minimum
valu
bottom
slope
left
variabl
determin
regress
perform
sampl
size
consist
independ
trial
carri
four
differ
day
account
possibl
variat
parasit
cultur
assay
perform
ml
cultur
tube
wt
dmso
control
tube
normal
effect
solvent
vitro
condit
valu
activ
compound
determin
run
assay
increas
drug
concentr
perform
regress
analysi
use
prism
softwar
graphpad
hela
cell
maintain
dulbecco
modifi
eagl
medium
contain
penicillinstreptomycin
foetal
bovin
serum
humifi
atmospher
doxorubicin
bleomycin
potent
compound
librari
ad
medium
cell
h
cultur
trypan
blue
assay
use
h
drug
treatment
calcul
cell
viabil
done
three
separ
trial
ensur
cytotox
result
consist
accuraci
cytotox
assay
valid
use
etoposid
posit
control
exhibit
valu
compar
report
valu
travelli
et
al
mono
dipropargyl
precursor
prepar
via
recent
report
protocol
involv
treatment
singh
et
al
mmol
propargyl
bromid
respect
treatment
mmol
propargyl
bromid
led
mixtur
ratio
evidenc
nmr
analysi
crude
reaction
mixtur
use
mmol
propargyl
bromid
result
isol
exclus
dipropargyl
product
observ
coupl
constant
j
hz
confirm
cisstereochemistri
product
scheme
nalkyl
azido
isatin
anoth
precursor
requir
synthesi
target
scaffold
prepar
initi
baseassist
nalkyl
isatin
dibromoalkan
follow
subsequ
reaction
sodium
azid
dmf
scheme
singh
et
al
synthes
precursor
util
synthesi
desir
mono
conjug
thu
reaction
mmol
presenc
copper
sulphat
sodium
ascorb
mixtur
led
isol
scheme
reaction
mmol
similar
condit
led
format
good
excel
yield
scheme
structur
hybrid
assign
basi
spectral
data
analyt
evid
compound
exampl
show
molecular
ion
peak
along
characterist
peak
nmr
spectra
nmr
spectrum
exhibit
presenc
singlet
correspond
methyl
proton
along
characterist
peak
correspond
methylen
proton
singlet
correspond
triazol
ring
proton
presenc
requisit
number
carbon
nmr
spectrum
along
two
characterist
peak
assign
isatin
ring
carbonyl
corrobor
assign
structur
synthes
mono
conjug
evalu
inhibitori
influenc
axen
vitro
growth
vaginali
strain
cultur
tym
diamond
media
h
tabl
list
data
obtain
initi
percentag
inhibit
screen
evid
tabl
activ
profil
test
compound
show
depend
substitu
ring
presenc
singledoubl
linker
increas
spacer
length
n
n
consider
effect
efficaci
test
compound
potent
test
compound
viz
select
age
inhibit
data
determin
valu
defin
minimum
concentr
requir
growth
inhibit
compound
exhibit
valu
respect
shown
tabl
curv
depict
fig
potent
compound
evalu
cytotox
hela
cell
result
cytotox
test
consist
show
viabil
compar
untreat
dmsotreat
cell
passag
cell
also
test
bleomycin
doxorubicin
concentr
positit
control
toxic
also
carri
assay
three
independ
day
multipl
trial
experi
compound
consist
show
compar
toxic
untreat
dmsotreat
hela
cell
test
present
commun
describ
synthesi
mono
conjug
along
preliminari
vitro
evalu
vaginali
synthes
scaffold
shown
prefer
ptolyl
substitu
ring
good
activ
potent
noncytotox
compound
exhibit
respect
howev
exact
inhibit
site
isatin
respons
activ
conjug
still
uncertain
studi
current
underway
